BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35945780)

  • 1. Development of a SETD2-related immune prognostic signature in clear cell renal cell carcinoma.
    Wang X; Xia Z; Li Z; Zhang C
    Medicine (Baltimore); 2022 Aug; 101(31):e29561. PubMed ID: 35945780
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Construction of a Novel Immune-Related lncRNA Pair Signature with Prognostic Significance for Kidney Clear Cell Renal Cell Carcinoma.
    Sun JX; Xia QD; Liu CQ; Xu JZ; Xun Y; Lu JL; Hu J; Wang SG
    Dis Markers; 2021; 2021():8800358. PubMed ID: 34512816
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A radiogenomics biomarker based on immunological heterogeneity for non-invasive prognosis of renal clear cell carcinoma.
    Gao J; Ye F; Han F; Jiang H; Zhang J
    Front Immunol; 2022; 13():956679. PubMed ID: 36177018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prediction of overall survival based upon a new ferroptosis-related gene signature in patients with clear cell renal cell carcinoma.
    Sun Z; Li T; Xiao C; Zou S; Zhang M; Zhang Q; Wang Z; Zhan H; Wang H
    World J Surg Oncol; 2022 Apr; 20(1):120. PubMed ID: 35422048
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Integrated analysis of immune-related gene subtype and immune index for immunotherapy in clear cell renal cell carcinoma.
    Bai D; Chen S; Feng H; Yin A; Lu J; Ma Y; Sugiyama H
    Pathol Res Pract; 2021 Sep; 225():153557. PubMed ID: 34329838
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of immune-related genes in clear cell renal cell carcinoma.
    Wan B; Liu B; Huang Y; Yu G; Lv C
    Aging (Albany NY); 2019 Dec; 11(23):11474-11489. PubMed ID: 31821170
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune-Associated Gene Signatures Serve as a Promising Biomarker of Immunotherapeutic Prognosis for Renal Clear Cell Carcinoma.
    Wang Q; Tang H; Luo X; Chen J; Zhang X; Li X; Li Y; Chen Y; Xu Y; Han S
    Front Immunol; 2022; 13():890150. PubMed ID: 35686121
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of an Immune Prognostic Model for Clear Cell Renal Cell Carcinoma Based on Tumor Microenvironment.
    Wang M; Song Q; Song Z; Xie Y
    Horm Metab Res; 2023 Jun; 55(6):402-412. PubMed ID: 37192644
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of a four immune-related genes signature based on an immunogenomic landscape analysis of clear cell renal cell carcinoma.
    Gao X; Yang J; Chen Y
    J Cell Physiol; 2020 Dec; 235(12):9834-9850. PubMed ID: 32452055
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of SETD2, but not H3K36me3, correlates with aggressive clinicopathological features of clear cell renal cell carcinoma patients.
    Liu L; Guo R; Zhang X; Liang Y; Kong F; Wang J; Xu Z
    Biosci Trends; 2017 May; 11(2):214-220. PubMed ID: 28260718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of a differentiation-related prognostic nomogram based on single-cell RNA sequencing in clear cell renal cell carcinoma.
    Xia ZN; Wu JG; Yao WH; Meng YY; Jian WG; Wang TD; Xue W; Yu YP; Cai LC; Wang XY; Zhang P; Li ZY; Zhou H; Jiang ZC; Zhou JY; Zhang C
    Sci Rep; 2022 Jun; 12(1):10973. PubMed ID: 35768519
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Computational construction of TME-related lncRNAs signature for predicting prognosis and immunotherapy response in clear cell renal cell carcinoma.
    Zhou L; Fang H; Guo F; Yin M; Long H; Weng G
    J Clin Lab Anal; 2022 Aug; 36(8):e24582. PubMed ID: 35808868
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients.
    Yao J; Liang Z; Duan L; G Y; Liu J; An G
    Heliyon; 2023 Jun; 9(6):e15925. PubMed ID: 37484396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A New Thinking: Deciphering the Aberrance and Clinical Implication of IGF Axis Regulation Pattern in Clear Cell Renal Cell Carcinoma.
    Jiang A; Wu X; Wang D; Wang A; Dong K; Liu B; Qu L; Luo P; Wang J; Tong Q; Wang L
    Front Immunol; 2022; 13():935595. PubMed ID: 35935986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of genes of prognostic value in the ccRCC microenvironment from TCGA database.
    Wan B; Liu B; Huang Y; Lv C
    Mol Genet Genomic Med; 2020 Apr; 8(4):e1159. PubMed ID: 32012488
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Validation of a Clinical Prognostic Model Based on Immune-Related Genes Expressed in Clear Cell Renal Cell Carcinoma.
    Ren S; Wang W; Shen H; Zhang C; Hao H; Sun M; Wang Y; Zhang X; Lu B; Chen C; Wang Z
    Front Oncol; 2020; 10():1496. PubMed ID: 32983989
    [No Abstract]   [Full Text] [Related]  

  • 17. The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma.
    Xu F; Guan Y; Xue L; Huang S; Gao K; Yang Z; Chong T
    BMC Cancer; 2020 Dec; 20(1):1207. PubMed ID: 33287763
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.
    Cao P; Wu JY; Zhang JD; Sun ZJ; Zheng X; Yu BZ; Cao HY; Zhang FL; Gao ZH; Wang W
    BMC Cancer; 2022 Jun; 22(1):691. PubMed ID: 35739510
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune-related risk prognostic model for clear cell renal cell carcinoma: Implications for immunotherapy.
    Chen R; Wu J; Liu S; Sun Y; Liu G; Zhang L; Yu Q; Xu J; Meng L
    Medicine (Baltimore); 2023 Aug; 102(34):e34786. PubMed ID: 37653791
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SETD2 mutation in renal clear cell carcinoma suppress autophagy via regulation of ATG12.
    González-Rodríguez P; Engskog-Vlachos P; Zhang H; Murgoci AN; Zerdes I; Joseph B
    Cell Death Dis; 2020 Jan; 11(1):69. PubMed ID: 31988284
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.